6-K - NeuroSense Therapeutics Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

NeuroSense Therapeutics reported year-end 2025 financial results with $11.1 million net loss, $0.2 million cash position, and PrimeC Phase 3 FDA clearance in ALS.

Key Takeaways

1Phase 2b PARADIGM showed 33% slowing in ALS progression over 18 months and 65% reduced risk of death with >14-month survival benefit.

2FDA cleared PARAGON Phase 3 trial for PrimeC in ALS in November 2025.

3PARADIGM results published in JAMA Neurology validating clinical and biological activity.

4R&D expenses increased 8.8% to $6.2 million; G&A up 16.6% to $4.9 million.

5Cash and equivalents fell to $166 thousand as of December 31, 2025 from $3.4 million prior year.

6Planned pre-NDS meeting with Health Canada in May 2026.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Results of Operations

Full Year 2025

Metric	Value	Basis	Prior Period
Research and development expenses	$-6.2K	GAAP	$-5.7K
General and administrative expenses	$-4.9K	GAAP	$-4.2K
Operating loss	$-11.1K	GAAP	$-9.9K
Net loss	$-11.1K	GAAP	$-10.2K
Basic and diluted net loss per share	$-0.44	GAAP	$-0.54

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

PRESS RELEASE, DATED MARCH 31, 2026